UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The sea urchin complement homologue, SpC3, functions as an opsonin

Journal of experimental biology, 2004-05, Vol.207 (Pt 12), p.2147-2155

2004

Volltextzugriff (PDF)

Echinoderm immunity and the evolution of the complement system

Developmental and comparative immunology, 1999-06, Vol.23 (4-5), p.429-442

1999

Volltextzugriff (PDF)

Echinoderm immunity

Advances in experimental medicine and biology, 2010, Vol.708, p.260

2010

Volltextzugriff (PDF)

The ancestral complement system in sea urchins

Immunological reviews, 2001-04, Vol.180 (1), p.16-34

2001

Volltextzugriff (PDF)

SpC3, the complement homologue from the purple sea urchin, Strongylocentrotus purpuratus, is expressed in two subpopulations of the phagocytic coelomocytes

Immunogenetics (New York), 2000-10, Vol.51 (12), p.1034-1044

2000

Volltextzugriff (PDF)

Constitutive expression and alternative splicing of the exons encoding SCRs in Sp152, the sea urchin homologue of complement factor B. Implications on the evolution of the Bf/C2 gene family

Immunogenetics (New York), 2004-10, Vol.56 (7), p.531-543

2004

Volltextzugriff (PDF)

Cold Acclimation-Associated Changes in Brown Adipose Tissue do Not Necessarily Indicate an Increase of Nonshivering Thermogenesis in C57BL/6J Mice

Physiology & behavior, 1996-11, Vol.60 (5), p.1285-1289

1996

Volltextzugriff (PDF)

Expression of SpC3, the sea urchin complement component, in response to lipopolysaccharide

Immunogenetics (New York), 2000-10, Vol.51 (12), p.1021-1033

2000

Volltextzugriff (PDF)

The ancestral complement system in sea urchins: Immunobiology of complement

Immunological reviews, 2001, Vol.180, p.16-34

2001

Volltextzugriff (PDF)

Expression and function of the complement homologue, SpC3, in the purple sea urchin, Strongylocentrotus purpuratus

Clow, Lori A

2001

Volltextzugriff (PDF)

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

The New England journal of medicine, 2013-08, Vol.369 (6), p.507-516

2013

Volltextzugriff (PDF)

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Haematologica (Roma), 2017-10, Vol.102 (10), p.1796-1805

2017

Volltextzugriff (PDF)

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-01, Vol.20 (1), p.43-56

2019

Volltextzugriff (PDF)

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

The New England journal of medicine, 2015-12, Vol.373 (25), p.2425-2437

2015

Volltextzugriff (PDF)

A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response

Clinical infectious diseases, 2024-02, Vol.78 (6), p.1462-1472

2024

Volltextzugriff (PDF)

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Blood, 2017-12, Vol.130, p.151-151

2017

Volltextzugriff (PDF)

Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study

Biology of blood and marrow transplantation, 2019-10, Vol.25 (10), p.2002-2007

2019

Volltextzugriff (PDF)

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Blood, 2018-11, Vol.132 (Supplement 1), p.691-691

2018

Volltextzugriff (PDF)

Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7057-7057

2013

Volltextzugriff (PDF)

730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib

Annals of hematology, 2015-02, Vol.94 (2), p.249-256

2015

Volltextzugriff (PDF)

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Blood, 2012-11, Vol.120 (21), p.904-904

2012

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The sea urchin complement homologue, SpC3, functions as an opsonin

Echinoderm immunity and the evolution of the complement system

Echinoderm immunity

The ancestral complement system in sea urchins

SpC3, the complement homologue from the purple sea urchin, Strongylocentrotus purpuratus, is expressed in two subpopulations of the phagocytic coelomocytes

Constitutive expression and alternative splicing of the exons encoding SCRs in Sp152, the sea urchin homologue of complement factor B. Implications on the evolution of the Bf/C2 gene family

Cold Acclimation-Associated Changes in Brown Adipose Tissue do Not Necessarily Indicate an Increase of Nonshivering Thermogenesis in C57BL/6J Mice

Expression of SpC3, the sea urchin complement component, in response to lipopolysaccharide

The ancestral complement system in sea urchins: Immunobiology of complement

Expression and function of the complement homologue, SpC3, in the purple sea urchin, Strongylocentrotus purpuratus

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy

730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection

Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib

Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Suchergebnisse filtern